Skip to content

Research paper

A Combination of Prebiotic Inulin and Oligofructose Improve Some of Cardiovascular Disease Risk Factors in Women with Type 2 Diabetes: A Randomized Controlled Clinical Trial.

Advanced pharmaceutical bulletin
Q1
Nov 2015
Citations: 80
Influential: 3
Interventional (Human) Studies
87

Study answer

What this study found

Overall, oligofructose-enriched inulin improved several cardiovascular and metabolic risk markers over 8 weeks. Fasting plasma glucose decreased by 19.2 mg/dL and HbA1c by 0.5%, while serum total cholesterol fell by 28.0 mg/dL, LDL-cholesterol by 22.0 mg/dL, and malondialdehyde by 1.7 nmol/ml. Between-group differences were significant for TAC and MDA, while TG, HDL-c, SOD, GSH-Px, and catalase changes were not significant between groups. No adverse events were reported, and the authors concluded the supplement may be a safe and effective adjunct in diabetes management.

Study & population
Randomized controlled clinical trial in adult women with type 2 diabetes who were overweight (BMI >25 kg/m2) and on stable oral antidiabetic therapy.
Intervention
The active regimen was 10 g/day of oligofructose-enriched inulin (Frutafit), given orally for 8 weeks in two 5 g doses taken with breakfast and dinner and water.
Key limitation
The trial was small, single-center, and short duration (8 weeks), which limits certainty and long-term inference.
View sourceOpen PDF

Original abstract

PURPOSE This trial was conducted to evaluate the effects of oligofructose-enriched inulin on some of cardiovascular disease risk factors in women with type 2 diabetes. METHODS 52 females (25<BMI<35 kg/m2) with type 2 diabetes were randomly assigned t…